BeOne Medicines price to free cash flow ONC
Market value divided by free cash flow over the last twelve months, since 2025.
- Today, Nov 3, 2026
- 30.2×
- Peer median
- 23.7×
BeOne Medicines' price to free cash flow is 30.2× as of Nov 3, 2026.
The median for 10 biotech stocks of a similar size is 23.7×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 30.9× | 26.4× | 73.6× |
| 2025 | 63.5× | 63.5× | 155× |
Against its peers
Companies in Biotechnology nearest BeOne Medicines' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| ONCBeOne Medicines | 30.2× |
| UTHRUnited Therapeutics | 23.7× |
| INCYIncyte | 12.7× |
| ALNYAlnylam Pharmaceuticals | 26.7× |
| EXELExelixis | 14.8× |
| REGNRegeneron Pharmaceuticals | 26.6× |
| NBIXNeurocrine Biosciences | 17.0× |
| HALOHalozyme Therapeutics | 18.2× |
| VRTXVertex Pharmaceuticals | n/m |
| TECHBIO-TECHNE | 43.3× |
| RGENRepligen | 87.2× |
| Peer median | 23.7× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on BeOne Medicines
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.